# Clinical Efficacy and Safety Comparative Study Between CMAB807 Injection and Prolia® .

> **NCT04591275** · PHASE3 · COMPLETED · sponsor: **Shanghai Biomabs Pharmaceutical Co., Ltd.** · enrollment: 278 (actual)

## Conditions studied

- Postmenopausal Osteoporosis

## Interventions

- **DRUG:** CMAB807 Injection
- **DRUG:** Prolia®

## Key facts

- **NCT ID:** NCT04591275
- **Lead sponsor:** Shanghai Biomabs Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-31
- **Primary completion:** 2024-11-01
- **Final completion:** 2024-11-01
- **Target enrollment:** 278 (ACTUAL)
- **Last updated:** 2025-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04591275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04591275, "Clinical Efficacy and Safety Comparative Study Between CMAB807 Injection and Prolia® .". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04591275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*